ImmunityBio (IBRX) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
14.7M
Gross Profit
14.7M
100.00%
Operating Income
-344.2M
-2,334.23%
Net Income
-413.6M
-2,805.32%
EPS (Diluted)
-$0.62
Balance Sheet Metrics
Total Assets
382.9M
Total Liabilities
871.1M
Shareholders Equity
-488.1M
Cash Flow Metrics
Operating Cash Flow
-357.1M
Free Cash Flow
-398.1M
Revenue & Profitability Trend
ImmunityBio Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 14.7M | 622.0K | 240.0K | 934.0K | 605.0K |
| Cost of Goods Sold | 0 | - | - | - | - |
| Gross Profit | 14.7M | - | - | - | - |
| Operating Expenses | 358.9M | 362.0M | 350.9M | 331.2M | 210.8M |
| Operating Income | -344.2M | -361.4M | -350.6M | -330.3M | -210.2M |
| Pre-tax Income | -413.6M | -583.9M | -417.3M | -349.8M | -226.0M |
| Income Tax | 0 | -40.0K | 34.0K | 9.0K | -1.8M |
| Net Income | -413.6M | -583.9M | -417.3M | -349.8M | -224.2M |
| EPS (Diluted) | -$0.62 | -$1.15 | -$1.04 | -$0.89 | -$0.58 |
Income Statement Trend
ImmunityBio Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 184.6M | 294.1M | 140.6M | 334.3M | 111.7M |
| Non-Current Assets | 198.3M | 210.4M | 221.8M | 134.6M | 109.7M |
| Total Assets | 382.9M | 504.5M | 362.4M | 468.9M | 221.4M |
| Liabilities | |||||
| Current Liabilities | 54.9M | 58.3M | 500.9M | 369.0M | 68.1M |
| Non-Current Liabilities | 816.1M | 1.0B | 311.3M | 343.8M | 271.7M |
| Total Liabilities | 871.1M | 1.1B | 812.2M | 712.8M | 339.9M |
| Equity | |||||
| Total Shareholders Equity | -488.1M | -585.9M | -449.8M | -243.9M | -118.5M |
Balance Sheet Composition
ImmunityBio Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -413.6M | -583.9M | -417.3M | -349.8M | -224.2M |
| Operating Cash Flow | -357.1M | -429.3M | -319.1M | -282.4M | -198.4M |
| Investing Activities | |||||
| Capital Expenditures | -6.9M | -30.6M | -78.2M | -13.1M | -1.7M |
| Investing Cash Flow | -12.2M | -30.5M | 48.5M | -84.9M | -19.8M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 208.2M | 561.5M | 408.3M | 842.5M | 150.0M |
| Free Cash Flow | -398.1M | -397.3M | -436.9M | -308.0M | -173.4M |
Cash Flow Trend
ImmunityBio Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-4.71
Forward P/E
-4.38
Price to Book
-4.02
Price to Sales
78.02
PEG Ratio
-4.38
Profitability Ratios
Profit Margin
100.00%
Operating Margin
-390.08%
Return on Equity
84.72%
Return on Assets
-55.62%
Financial Health
Current Ratio
2.22
Debt to Equity
-1.39
Beta
-0.06
Per Share Data
EPS (TTM)
-$0.57
Book Value per Share
-$0.69
Revenue per Share
$0.04
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ibrx | 2.4B | -4.71 | -4.02 | 84.72% | 100.00% | -1.39 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Blueprint Medicines | 8.3B | -120.00 | 24.19 | -47.71% | -27.70% | 208.50 |
| Roivant Sciences | 7.8B | 1.95 | 1.71 | -12.54% | 96.86% | 1.93 |
| Bio-Techne | 7.9B | 60.87 | 3.92 | 6.53% | 10.89% | 20.99 |
Financial data is updated regularly. All figures are in the company's reporting currency.